Cargando…

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab

Detalles Bibliográficos
Autores principales:	Ohshima, Yuichiro, Kinoshita, Yumi, Akita, Yoichi, Tamada, Yasuhiko, Watanabe, Daisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Dermatological Association; The Korean Society for Investigative Dermatology 2013
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870222/ https://www.ncbi.nlm.nih.gov/pubmed/24371401 http://dx.doi.org/10.5021/ad.2013.25.4.496

Ejemplares similares

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis
por: Matsuura-Otsuki, Yuki, et al.
Publicado: (2017)

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
por: Mease, P J, et al.
Publicado: (2008)

Dramatic Response of Nail Psoriasis to Infliximab
por: Safa, Gilles, et al.
Publicado: (2011)

Dramatic response to infliximab in refractory neurosarcoidosis
por: Chintamaneni, Sreekanth, et al.
Publicado: (2010)

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
por: Baranauskaite, Asta, et al.
Publicado: (2011)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
por: Castro, Karla R., et al.
Publicado: (2011)

Development of Eosinophilic Fasciitis during Infliximab Therapy for Psoriatic Arthritis
por: Hariman, Richard, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

A Case of Phlegmonous Gastritis in a Patient with Psoriatic Arthritis on Infliximab
por: De Davide, Laurence, et al.
Publicado: (2018)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Adalimumab/infliximab: Lower serologic response: 6 case reports
Publicado: (2022)

Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis
por: Mase, Oliver, et al.
Publicado: (2023)

Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study
por: D'Angelo, Salvatore, et al.
Publicado: (2019)

Symptomless Pulmonary Cryptococcosis in a Psoriatic Arthritis Patient during Infliximab Therapy
por: Yamada, Saori, et al.
Publicado: (2016)

Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study
por: Eng, Grith P., et al.
Publicado: (2015)

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study
por: Ortea, Ignacio, et al.
Publicado: (2016)

Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
por: Gudbjornsson, Bjorn, et al.
Publicado: (2018)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
por: Landewé, Robert, et al.
Publicado: (2019)

Brain abscess in a patient with psoriatic arthritis treated with adalimumab: A case report
por: Lo, Yu-Pei, et al.
Publicado: (2020)

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
por: Wcisło-Dziadecka, Dominika, et al.
Publicado: (2020)

The influence of adalimumab treatment on the systemic gene expression in patients with psoriatic arthritis – preliminary report
por: Krawczyk, Agata, et al.
Publicado: (2021)

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
por: D’Angelo, Salvatore, et al.
Publicado: (2017)

Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
por: Kim, Eun Sil, et al.
Publicado: (2023)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Digital Vasculitis in a Patient with Rheumatoid Arthritis Responded Well to Adalimumab
por: Kobak, Senol, et al.
Publicado: (2014)

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
por: van der Bijl, Arie E., et al.
Publicado: (2008)

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
por: Doan, Quan V., et al.
Publicado: (2006)

Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis
por: Trídico, Lívia Arroyo, et al.
Publicado: (2017)

Management of Crohn’s disease in poor responders to adalimumab
por: de Boer, Nanne KH, et al.
Publicado: (2014)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ff4lmcudl914vdt1lr2nm5cs07